University of North Carolina, Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina 27599-7295

1 studies enrolling now · 27 studies all time

What they study most

AML, Acute Myeloid Leukemia, Acute-graft-versus-host Disease, Basal Cell Carcinoma, Bladder Cancer, Breast Cancer, Cancer, Cancer of the Ureter, Carcinoma, Colorectal Cancer Metastatic, Distal Urethral Cancer, Estrogen Receptor-negative Breast Cancer

Studies at this site

• A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers — Recruiting now
• Adjuvant Avelumab in Merkel Cell Cancer — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD — Completed
• Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies — Running, not enrolling
• Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML — Stopped early
• Evolutionary Therapy for Rhabdomyosarcoma — Running, not enrolling
• A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV — Running, not enrolling
• Afatinib in Advanced Refractory Urothelial Cancer — Stopped early
• Safety and Tolerability of Intravenous Administration of ICVB-1042 — Stopped early
• Safety of Pregnancy in BRCA Mutated Breast Cancer Patients — Completed
• Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant — Stopped early
• Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) — Stopped early
• Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer — Completed
• UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch — Completed
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma — Stopped early
• Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients — Completed
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma — Stopped early
• Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer — Stopped early
• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma — Completed
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC — Stopped early
• Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions — Completed
• Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC — Completed
• Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer — Stopped early
• Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer — Completed
• A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) — Completed
• Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim — Completed
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors — Completed